Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristics of Affected Limb Pain and Associated Factors in Young Adult Survivors of Lower Limb Osteosarcoma in Japan.

Journal of adolescent and young adult oncology·2026
Same author

Safety of carbon-ion radiotherapy for prostate cancer after rectal surgery: a single-institution retrospective study.

Journal of radiation research·2026
Same author

MUC4-Positive Fibroblastoma: Clinicopathological and Molecular Analysis of 7 Cases.

The American journal of surgical pathology·2026
Same author

Analysis of the Relationship Between Survival and Postoperative Infection in Patients With Osteosarcoma.

Journal of surgical oncology·2026
Same author

HMGA2 expression in CIC-rearranged sarcoma and other small round/epithelioid cell tumours.

Histopathology·2026
Same author

Selective MYC 5' amplification in postirradiation/lymphedema-associated angiosarcoma.

Virchows Archiv : an international journal of pathology·2026

Related Experiment Video

Updated: Jan 13, 2026

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.7K

Carbon Ion Radiotherapy for Retroperitoneal Sarcoma: A Single-Institution Study.

Reiko Imai1, Tsukasa Yonemoto2, Nobuhito Araki3

  • 1QST Hospital, National Institute of Quantum Science and Technology,4-9-1, Anagawa, Inage, Chiba Shi 263-8555, Chiba, Japan.

Cancers
|October 29, 2025
PubMed
Summary

Carbon ion radiotherapy (CIRT) offers a definitive treatment for unresectable retroperitoneal sarcoma (RPS). This study shows promising survival and local control rates, with manageable late adverse events in patients with RPS.

Keywords:
carbon ion radiotherapycharged particle therapyradiation therapyretroperitoneal sarcomasoft tissue sarcoma

More Related Videos

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

14.8K
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

16.2K

Related Experiment Videos

Last Updated: Jan 13, 2026

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.7K
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

14.8K
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

16.2K

Area of Science:

  • Oncology
  • Radiation Oncology
  • Surgical Oncology

Background:

  • Surgery is the primary treatment for retroperitoneal sarcoma (RPS).
  • Definitive treatment strategies for unresectable RPS or those with insufficient margins are unclear.
  • Carbon ion radiotherapy (CIRT) is an option for unresectable RPS.

Purpose of the Study:

  • To evaluate the effectiveness of CIRT in patients with unresectable RPS.
  • To assess survival rates, local control, and recurrence-free survival after CIRT.
  • To determine the incidence of late adverse events following CIRT.

Main Methods:

  • Retrospective analysis of 76 patients with unresectable RPS treated with CIRT.
  • Standardized CIRT protocol: 70.4 Gy in 16 fractions over 4 weeks, with respiratory gating and spot scanning.
  • Prognosis confirmed up to 2022 for 95% of patients.

Main Results:

  • 3- and 5-year overall survival rates of 68.3% and 49.4%; median overall survival of 58.1 months.
  • 3- and 5-year local control rates of 79.0% and 72.0%.
  • Grade 3 or higher late adverse events occurred in 5.2% of patients.

Conclusions:

  • CIRT is a definitive treatment option for unresectable RPS.
  • CIRT demonstrates significant efficacy in local control and survival for RPS.
  • Multicenter studies are recommended to validate CIRT effectiveness in larger cohorts.